特邀社论：关于豪等人所著的《肽受体放射性核素治疗可提高胃肠胰神经内分泌肿瘤切除术后进展患者的生存率》 - Suppr

Suppr

超能文献

Invited Editorial Regarding "Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors", by Howe et al.

作者信息

Pommier Rodney F

机构信息

Division of Surgical Oncology, Oregon Health & Science University, Portland, OR, USA.

出版信息

Ann Surg Oncol. 2025 Apr;32(4):2253-2255. doi: 10.1245/s10434-024-16834-0. Epub 2025 Jan 27.

DOI:10.1245/s10434-024-16834-0

PMID:39865205

Abstract

摘要

相似文献

Invited Editorial Regarding "Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors", by Howe et al.特邀社论：关于豪等人所著的《肽受体放射性核素治疗可提高胃肠胰神经内分泌肿瘤切除术后进展患者的生存率》

Ann Surg Oncol. 2025 Apr;32(4):2253-2255. doi: 10.1245/s10434-024-16834-0. Epub 2025 Jan 27.

Surgery enhances the effectiveness of peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumors.手术可提高肽受体放射性核素治疗转移性胃肠胰神经内分泌肿瘤的疗效。

Surgery. 2025 Jan;177:108834. doi: 10.1016/j.surg.2024.06.065. Epub 2024 Oct 11.

Peptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors.肽受体放射性核素治疗可改善胃肠胰神经内分泌肿瘤切除术后进展患者的生存率。

Ann Surg Oncol. 2025 Feb;32(2):1136-1148. doi: 10.1245/s10434-024-16463-7. Epub 2024 Nov 6.

Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review.肽受体放射性核素治疗（PRRT）在胃肠胰腺和肺神经内分泌肿瘤中的应用：最新综述

J Clin Med. 2021 Mar 18;10(6):1267. doi: 10.3390/jcm10061267.

Peptide receptor radionuclide therapy with somatostatin analogs beyond gastroenteropancreatic neuroendocrine tumors.使用生长抑素类似物进行肽受体放射性核素治疗，治疗范围超出胃肠胰神经内分泌肿瘤。

J Neuroendocrinol. 2025 Mar;37(3):e70013. doi: 10.1111/jne.70013. Epub 2025 Mar 10.

Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.177Lu-奥曲肽肽受体放射性核素治疗后高分化胃肠胰神经内分泌肿瘤患者长期预后的预测因素

J Nucl Med. 2014 Feb;55(2):183-90. doi: 10.2967/jnumed.113.125336. Epub 2014 Jan 16.

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.肽受体放射性核素治疗胃肠胰神经内分泌肿瘤患者。

Semin Nucl Med. 2010 Mar;40(2):78-88. doi: 10.1053/j.semnuclmed.2009.10.004.

Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors.难治性胃肠胰神经内分泌肿瘤

Cancers (Basel). 2022 Sep 29;14(19):4769. doi: 10.3390/cancers14194769.

Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.镥-177治疗神经内分泌肿瘤：文献综述

Cureus. 2019 Jan 30;11(1):e3986. doi: 10.7759/cureus.3986.

Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors.胃肠胰神经内分泌肿瘤靶向肽受体放射性核素正电子发射断层成像与治疗的现状与未来。

World J Gastroenterol. 2022 May 7;28(17):1768-1780. doi: 10.3748/wjg.v28.i17.1768.

本文引用的文献

[Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.[吕]吕-DOTA-TATE 联合长效奥曲肽对比高剂量长效奥曲肽治疗新诊断的晚期 2-3 级、高分化胃肠胰神经内分泌肿瘤（NETTER-2）：一项开放标签、随机、3 期研究。

Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5.

Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lu-Dotatate 联合长效奥曲肽与高剂量长效奥曲肽治疗肠神经内分泌肿瘤患者（NETTER-1）：一项开放标签、随机、对照、III 期临床试验的最终总生存和长期安全性结果。

Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.

Outcomes of cytoreductive operations for peritoneal carcinomatosis with or without liver cytoreduction in patients with small bowel neuroendocrine tumors.伴有或不伴有肝减瘤术的细胞减灭术治疗小肠类癌肿瘤腹膜转移的疗效。

Surgery. 2021 Jan;169(1):168-174. doi: 10.1016/j.surg.2020.03.030. Epub 2020 May 27.

Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors.扩大的肝转移瘤减瘤标准也适用于胰腺神经内分泌肿瘤。

Surgery. 2018 Jan;163(1):218-225. doi: 10.1016/j.surg.2017.05.030. Epub 2017 Nov 2.

Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验

N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.

Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?神经内分泌转移瘤的肝脏定向手术：最佳策略是什么？

Surgery. 2016 Jan;159(1):320-33. doi: 10.1016/j.surg.2015.05.040. Epub 2015 Oct 9.

Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients.类癌肝减瘤的扩展标准：维持生存率并增加符合条件的患者数量。

Surgery. 2014 Dec;156(6):1369-76; discussion 1376-7. doi: 10.1016/j.surg.2014.08.009. Epub 2014 Nov 11.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验